Compare Kimberly Clark Corp (KMB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs TG Therapeutics Inc — how do they compare? Kimberly Clark Corp trades at $97.47 (market cap $32.51B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Kimberly Clark Corp is far larger — about 4× TG Therapeutics Inc's market cap, and Kimberly Clark Corp pays a 5.24% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and TG Therapeutics Inc for 16 Days on average.
| KMB | TGTX | |
|---|---|---|
Market Cap | $32.51B | $8.16B |
Volume | 6,139,913 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $59.06 |
52-Week Low | $93.05 | $26.94 |
Typical Hold Time | 93 Days | 16 Days |
Enterprise Value | $38.07B | $8.37B |
Dividend Yield | 5.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $98.02, up 1.6% on the day, showing modest recovery from recent weakness. The stock faces bearish technical signals with support at $96 and resistance at $98. Fundamentally, the company maintains strong profitability with 11.79% net margins and consistent dividend payments, though revenue declined to $16.45B in 2025. Recent executive transitions and the pending Kenvue acquisition create both uncertainty and strategic opportunity.
KMB offers a compelling dividend yield above 5% with 54 consecutive years of increases, but faces execution risks from the Kenvue integration. Analyst consensus targets $117.25 (19% upside) with mixed sentiment (32% buy, 58% hold). The stock presents value for income investors but requires careful monitoring of acquisition progress and cash flow sustainability.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
